linjc16/ctgov huggingface dataset:
MMP-9 Monitoring Particulate Cerebral Embolisation

Study Overview
=================
Brief Summary
-----------------
In carotid endarterectomy(CEA) surgery, the dynamic changes of plasma MMP9 concentration cross CEA will be identified. And the part of patients suffered particulate cerebral embolic injury, their MMP9 level will increase in the early stage after CEA.

Official Title
-----------------
Dynamic Changes of MMP9 Concentration Cross Carotid Endarterectomy Monitoring Particulate Cerebral Embolisation

Conditions
-----------------
Cerebral Embolic Damage

Intervention / Treatment
-----------------
* Procedure: vein blood collection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: -All patients enrolled had at least ≥70% unilateral or bilateral stenosis of Internal -Carotid Artery， or those who had a <70% stenosis but obvious cerebral ischema symptoms had been existed. Exclusion Criteria: Exclusion criteria included poor temporal window Refused to cooperate with us Nonatheromatous such as takayasu arteritis and fibromuscular dysplasia.

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| carotid endarterectomy (CEA)<br>CEA patients with vein blood collection | Procedure: vein blood collection<br>* 5 ml peripheral vein blood samples were collected from each patient admitted to our study at the following time-points：Pre-operative（morning of surgery），just before declamping，30mins after declamping and post-operative（12h）.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| postoperative ischemic stroke |  | 7 days after surgery | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| postoperative elevation of plasma MMP9 |  | perioperative phage |
Training Load Management in Three Professional Tennis Players During COVID-19 Lockdown: a Case Series Study

Study Overview
=================
Brief Summary
-----------------
Research describing training load management during COVID-19 enforced home training in professional tennis players is lacking. Therefore, the main objective of this case series is to describe in detail the training load management and progression of three professional tennis players before, during and after COVID-19 pandemic lockdown.

Detailed Description
-----------------
Research describing training load management during COVID-19 enforced home training in professional tennis players is lacking. Therefore, the main objective of this case series is to describe in detail the training load management and progression of three professional tennis players before, during and after COVID-19 pandemic lockdown.

Official Title
-----------------
Training Load Management in Three Professional Tennis Players During COVID-19 Lockdown: a Case Series Study

Conditions
-----------------
Monitor Training Load

Intervention / Treatment
-----------------
* Other: Training load


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: tennis players training in argentina Exclusion Criteria: -
Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| P1<br> | Other: Training load<br>* Monitoring training load during covid<br>|
| P2<br> | Other: Training load<br>* Monitoring training load during covid<br>|
| P3<br> | Other: Training load<br>* Monitoring training load during covid<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Training load | session RPE | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
training load, tennis, covid
Use of Granulocyte Colony-stimulating Factor for the Treatment of Recurrent Implantation Failure in IVF Patients

Study Overview
=================
Brief Summary
-----------------
The investigators use granulocyte colony-stimulating factor (GCSF) for the treatment of recurrent implantation failure in IVF patient with cause unknown or due to thin endometrium. Several studies showed that GCSF improves embryo development and implantation and increase pregnancy rate.

Detailed Description
-----------------
The investigators use granulocyte colony-stimulating factor (GCSF) for the treatment of repeated implantation failure (5 cycles) in IVF patient with cause unknown or due to thin endometrium. we intend to treat with GCSF during the IVF cycle if thin endometrium (<6 mm) is the cause for the treatment failure, and during the implantation window if cause unknown.

Official Title
-----------------
Phase 1 Study of the Use of Granulocyte Colony-stimulating Factor for the Treatment of Repeated Implantation Failure in IVF Patients

Conditions
-----------------
Infertility

Intervention / Treatment
-----------------
* Drug: neupogen administration for women with recurrent IVF failure


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: women after 5 failures in IVF cycles with cause unknown. women after 5 failures in IVF due to thin endometrium (<6 mm) and unresponsive to estrogen supplements. Exclusion Criteria: history of hematology disease allergy to GCSF neutrophilia severe lower back pain liver dysfunction hyperuricemia a recent febrile disease or pneumonia rheumatoid arthritis 9. sickle cell disease-

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: neupogen<br> | Drug: neupogen administration for women with recurrent IVF failure<br>* neupogen 300 mcg - twice<br>* Other names: filgrastim;|
| No Intervention: no intervantion<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| pregnancy rate |  | 18 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| endometrial thickness during IVF treatment |  | 18 months | 
| endometrial thickness |  | 18 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
improving pregnancy rate and endometrial thickness
Change In Diaphragmatic Thickness Predicts Extubation Success

Study Overview
=================
Brief Summary
-----------------
We will investigate whether measurement of the change in thickness of the diaphragm during the respiratory cycle by ultrasound can predict extubation success in a 48 hour window. We will also asses whether this is only possible on low levels of pressure support as has been shown previously, or if this technique retains its predictive power at higher levels of pressure support.

Official Title
-----------------
Can the Diaphragm Predict the Course of Mechanical Ventilation? A Prospective Study Evaluating Several M-Mode Ultrasound Measured Diaphragmatic Parameters and Their Effects on Weaning From Mechanical Ventilation

Conditions
-----------------
Mechanical Ventilation Complication

Intervention / Treatment
-----------------
* Procedure: Diaphragm Ultrasound


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age greater than 18, ventilated for >24 hours Exclusion Criteria: already chronically on mechanical ventilatory support, already has tracheostomy, has pathology that obscures visualization of the right hemidiaphragm, has acute stroke either hemorrhagic or ischemic, cannot identify appropriate decision maker to get informed consent.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Main Cohort<br>all patients enrolled will have an ultrasound of their diaphragm performed once they are on a pressure support trial. Intervention: Diaphragm Ultrasound | Procedure: Diaphragm Ultrasound<br>* Once on a pressure support weaning trial, enrolled subjects will have an ultrasound of their right hemidiaphragm performed on three levels of pressure support: 15/5 10/5 and 5/5<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Extubation Success | Discontinuation from mechanical ventilation in 48 hours from ultrasound PI has left the institution. Efforts made to contact the PI were unsuccessful. No study data available. | 48 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Re-intubation | Reinstitution of mechanical ventilation within 48 hours of extubation PI has left the institution. Efforts made to contact the PI were unsuccessful. No study data available. | 48 hours from removal of ventilatory support | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Diaphragm, Ventilators, Mechanical
Determination of the Nature of the Endogenous Ligand of TREM-1 and Its Use as a New Diagnostic Biomarker in Sepsis

Study Overview
=================
Brief Summary
-----------------
Step 1: Identification and characterisation of the TREM1L protein from samples already available characterised at the hospital Central of Nancy Step 2: Study of the isoforms of TREM1L in correlation with the prognosis of sepsis, Step 3: implementation of assay methods for TREM1L (ELISA or SUPRA MS) Step 4: Validation of assays for TREM1L and its isoforms in a larger number of subjects (inclusion of samples from Dijon CHU and Besançon CHU)

Conditions
-----------------
Sepsis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients hospitalised in a Medical Intensive Care unit whatever the reason written informed consent obtained Exclusion Criteria: patients less than 18 years old or under guardianship, persons without national health insurance.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| plasma concentrations of sTREM-1 |  | baseline |
Evaluate Safety & Efficacy of Condroflex in Subjects With OA

Study Overview
=================
Brief Summary
-----------------
Primary Objective: To compare, after 12 weeks of double-blind treatment, the evolution of the improvement of pain (at rest and during / after exercise) in the questionnaire WOMAC (Western Ontario and McMaster Universities Arthritis Index), achieved with Condroflex ® oral administration(sulfate glucosamine + chondroitin sulfate sodium) in association with therapeutic exercises, compared to placebo in association with therapeutic exercises in individuals with knee OA and not exposed to prior treatment with the products under investigation.

Detailed Description
-----------------
To have osteoarthritis degree 2 or 3 / To be capable to consent

Official Title
-----------------
Phase 3 Study, to Evaluate Safety & Efficacy of the Association Condroflex + Therapeutic Exercises Compared to Placebo + Therapeutic Exercises, in Subjects With Knee OA

Conditions
-----------------
Elderly, Treatment, Osteoarthritis

Intervention / Treatment
-----------------
* Other: condroflex and exercise
* Other: sugar pill and exercise


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: to have knee osteoarthritis degree 2 or 3 to be capable to consent Exclusion Criteria: previous drug treatment concomitant diseases concomitant drugs

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: condroflex and exercise<br>assent arm | Other: condroflex and exercise<br>* 1 sachet oral once a day by 12 Weeks / therapeutic exercise 3 times a week<br>* Other names: glucosamine sulph + chondroitin sulph and therapeutic exerc.;|
| Placebo Comparator: sugar pill and exercise<br>sugar pill arm | Other: sugar pill and exercise<br>* 1 sachet oral once a day by 12 Weeks / therapeutic exercise 3 times a week<br>* Other names: Placebo Comparator and therapeutic exerc.;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| improvement of pain |  | 12 week | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| rigidity restriction |  | 12 week | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
chondroitin, glucosamine, osteoarthritis
Functional-three-dimensional Reconstruction of Liver by 99MTc-GSA-SPECT Scan

Study Overview
=================
Brief Summary
-----------------
The aims of this study were divided into three parts: To develop a new software to carry out the functional-three- dimensional-reconstruction of the liver by 99mTc-GSA-SPECT scintigraphy To probe a new dynamic model of the metabolism of the 99mTc-GSA. To evaluate the liver function by 99mTc-GSA-SPECT scintigraphy before surgical treatment. Study design: Collectivity type: Prospective，randomized, controlled, multi-central clinical study. Patients: The subjects were from different hospitals including: Peking Union Medical College Hospital (PUMCH). Study arrangement: This study was consisted of three parts:

Official Title
-----------------
Functional-three-dimensional Reconstruction and Functional Evaluation of Liver by 99MTc-GSA-SPECT Scintigraphy

Conditions
-----------------
Cirrhosis, Hepatic Carcinoma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients that with benign tumor、hepatitis and hepatic carcinoma (with or without cirrhosis)diagnosed by examination of CT, ultrasound-B, and/or pathology.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Normal control<br>Subjects without liver cirrhosis and normal volunteers. | |
| Cirrhosis group<br>Subjects with liver cirrhosis. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Hepatic Carcinoma, Cirrhosis
Effectiveness and Security Testing of a Mobile App for Self-Managing Emotion Dysregulation

Study Overview
=================
Brief Summary
-----------------
To assess the effectiveness and security of a mobile App (beta version) for people with borderline traits recruited from a non-clinical population of college students in Barcelona (Spain). The main primary outcome will be the severity of the emotional dysregulation. Forty participants will use the mobile app over 6 months. This group while be compared at post-treatment and at 3-month follow-up with other 40 participants (control group) with any intervention.

Official Title
-----------------
Effectiveness and Security Testing of a Mobile App for Self-Managing Emotion Dysregulation in a Non-Clinical Population With Borderline Traits: A Randomized Controlled Trial

Conditions
-----------------
Emotional Dysregulation

Intervention / Treatment
-----------------
* Device: Mobile app


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Borderline traits Aged between 18 to 65 years College students Exclusion Criteria: None

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Intervention group<br>Those who will use the mobile app | Device: Mobile app<br>* Mobile app for self-managing emotional dysregulation<br>|
| No Intervention: Non-intervention group<br>Those who will not use the mobile app | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Emotion dysregulation severity | Severity of emotional dysregulation as measured by a single score from the The DERS scale (Difficulties in Emotion Regulation scale) (range: 0-88; the higher the score, the more severe the emotion dysregulation severity). | 9-month | 
| smartphone addiction | Severity of smartphone addiction as measured by the Spanish version of the The Smartphone Addiction Scale (SAS) (range: 10-60; the higher the score, the more severe the smartphone addiction severity). | 9-month |
Bed Rest for Idiopathic Sudden Sensorineural Hearing Loss

Study Overview
=================
Brief Summary
-----------------
sudden sensorineural hearing loss: idiopathic in most cases 5-20/100,000 new cases annually in the U.S no establishes pathogenesis treated with oral steroids in most cases  50% improvement in hearing levels bed rest - acceptable treatment, not well investigated

Official Title
-----------------
Bed Rest for Idiopathic Sudden Sensorineural Hearing Loss

Conditions
-----------------
Sudden Loss of Hearing

Intervention / Treatment
-----------------
* Procedure: bed rest
* Drug: prednisone - oral corticosteroid 1mg/kg/D for 1 week


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients with sudden sensorineural hearing loss Exclusion Criteria: age less than 16 years contraindication for oral steroid treatment prior steroid treatment for hearing loss pregnent women

Ages Eligible for Study
-----------------
Minimum Age: 16 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: bed rest|nan|
|Drug: prednisone - oral corticosteroid 1mg/kg/D for 1 week|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| hearing improvement |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Bed rest for idiopathic sudden sensorineural hearing loss
U-clip Pilot Study in Plastic Surgery

Study Overview
=================
Brief Summary
-----------------
This study will assess the nitinol U-clip as an alternative to conventional microsurgical suture for arterial anastomoses in free tissue transfer.

Detailed Description
-----------------
Within Scott & White, a total of 25 free flaps will be performed using U-clips for microvascular anastomoses in lieu of traditional suturing techniques. Each of these free flaps may be in individual patients or two anastomoses may be included in one patient. Historical controls will be used for comparison of complication rates of U-clip versus sutured anastomoses. Postoperatively, the study participants will be evaluated at 2 weeks (+/- 1 week) and at 3 months (+/- 1 month) follow up.

Official Title
-----------------
A Prospective Evaluation of U-clips for Arterial Microvascular Anastomoses

Conditions
-----------------
Microvascular Anastomoses

Intervention / Treatment
-----------------
* Device: nitinol u-clip


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: either gender any ethnicity patient requiring free tissue transfer for complex wound coverage or reconstruction patient having arterial anastomotic diameter of at least 2 mm patient capable of giving informed consent Exclusion Criteria: less than 18 years of age allergy to nitinol or any of its components (nickel or titanium) pregnancy known coagulopathy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: no arms<br>all patients will receive the treatment - there is only one arms | Device: nitinol u-clip<br>* The U-clip is comprised of nitinol, an alloy of nickel and titanium.<br>* Other names: Coalescent Surgical U-CLIPTbl;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Flap failure rate compared to published rate for conventional suture anastomoses |  | will be measured 3 months postoperative (+/- 2 weeks) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rapid, reproducible, sutureless microvascular arterial anastomoses in free flaps without compromising patient outcomes. |  | data collected at 3 months postoperative (+/- 2 weeks) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
anastomoses